SPRINGWORKS THERAPEUTICS, INC. (SWTX): Price and Financial Metrics


SPRINGWORKS THERAPEUTICS, INC. (SWTX): $23.83

-0.65 (-2.66%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SWTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SWTX Stock Price Chart Interactive Chart >

Price chart for SWTX

SWTX Price/Volume Stats

Current price $23.83 52-week high $74.97
Prev. close $24.48 52-week low $13.60
Day low $23.70 Volume 160,600
Day high $24.41 Avg. volume 837,912
50-day MA $25.51 Dividend yield N/A
200-day MA $35.53 Market Cap 1.49B

SPRINGWORKS THERAPEUTICS, INC. (SWTX) Company Bio


Springworks Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It identifies pathways for drug development for patients with severe rare diseases and cancer. The firm's products include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.


SWTX Latest News Stream


Event/Time News Detail
Loading, please wait...

SWTX Latest Social Stream


Loading social stream, please wait...

View Full SWTX Social Stream

Latest SWTX News From Around the Web

Below are the latest news stories about SPRINGWORKS THERAPEUTICS INC that investors may wish to consider to help them evaluate SWTX as an investment opportunity.

SpringWorks Therapeutics to Participate in the Evercore ISI 5th Annual HealthCONx Conference

STAMFORD, Conn., Nov. 22, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference, taking place virtually on Tuesday, November 29, 2022 at 4:20 p.m. ET. To access the live webcast please visit the Events & Presentations pag

Yahoo | November 22, 2022

SpringWorks Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

– Presented Positive Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022 – – Expanded Global, Non-Exclusive Collaboration with GSK to Continue Evaluating Nirogacestat in Combination with Belantamab Mafodotin (Belamaf) in Patients with Multiple Myeloma – – Dosed First Patient in Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors – – Strengthened Fi

Yahoo | November 3, 2022

Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma

Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their collaboration with SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, for the development of a systems pharmacology model in multip

Yahoo | November 1, 2022

Is SpringWorks Therapeutics Inc. (NASDAQ: SWTX) Still A Loss Stock Despite Being Down -55.91% YTD?

During the last session, SpringWorks Therapeutics Inc. (NASDAQ:SWTX)’s traded shares were 0.66 million. At the end of the trading day, the stock’s price was $27.33, reflecting an intraday loss of -4.84% or -$1.39. The 52-week high for the SWTX share is $77.70, that puts it down -184.3 from that peak though still a striking 50.24% … Is SpringWorks Therapeutics Inc. (NASDAQ: SWTX) Still A Loss Stock Despite Being Down -55.91% YTD? Read More »

Marketing Sentinel | October 8, 2022

H.C. Wainwright Reaffirms Their Buy Rating on Springworks Therapeutics (SWTX)

E ratio of -5.83.

Christine Brown on TipRanks | September 30, 2022

Read More 'SWTX' Stories Here

SWTX Price Returns

1-mo -2.30%
3-mo -12.07%
6-mo N/A
1-year -65.20%
3-year 10.48%
5-year N/A
YTD -61.55%
2021 -14.53%
2020 88.41%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7079 seconds.